Volume 29, Issue 1 (Iran South Med J 2026)
Iran South Med J 2026, 29(1): 26-39 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Derakhshan S, Moassesghafari B, Roshani D. Perfusion Distribution Changes in Gated-SPECT Myocardial Perfusion Imaging after Chemotherapy in Patients with Breast Cancer. Iran South Med J 2026; 29 (1) :26-39
URL: http://ismj.bpums.ac.ir/article-1-2507-en.html
URL: http://ismj.bpums.ac.ir/article-1-2507-en.html
1- Department of Radiotherapy, School of Paramedical Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran , siamak.derakhshan@muk.ac.ir
2- Department of Radiology, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
3- Department of Epidemiology and Biostatistics, School of Medicine, Kurdistan University of medical Sciences, Sanandaj, Iran
2- Department of Radiology, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran
3- Department of Epidemiology and Biostatistics, School of Medicine, Kurdistan University of medical Sciences, Sanandaj, Iran
Abstract: (216 Views)
Background: Early detection of chemotherapy-induced cardiotoxicity plays an important role in preventing its progression. This study aimed to investigate early changes in myocardial perfusion distribution after chemotherapy with doxorubicin in patients with breast cancer.
Materials and Methods: Resting myocardial perfusion imaging was performed before and after chemotherapy in 61 women with breast cancer without a history of cardiovascular disease or radiotherapy. The standard deviation and 95% bandwidth of the histogram of the mean uptake in the segments of Bull's-eye image were compared before and after chemotherapy. The relationship of changes in these indices with the cumulative dose of doxorubicin, age and body mass index of the patients were also investigated.
Results: The mean percentage of uptake in the Bull's-eye segments was 69.60 before and 68.10 after chemotherapy (P>0.05). The standard deviation and 95% bandwidth of histogram of the mean segmental uptake before chemotherapy were 5.48 and 18.58, respectively, which increased to 5.56 and 19.52, respectively, after chemotherapy. This increase was mainly seen in patients who received a cumulative dose of more than 400 mg of doxorubicin. However, none of these changes were statistically significant (P>0.05). No significant association was observed between changes in left ventricular perfusion distribution and either age or body mass index.
Conclusion: Chemotherapy did not produce significant early changes in left ventricular myocardial perfusion. However, further studies with pixel-based myocardial perfusion imaging are recommended.
Materials and Methods: Resting myocardial perfusion imaging was performed before and after chemotherapy in 61 women with breast cancer without a history of cardiovascular disease or radiotherapy. The standard deviation and 95% bandwidth of the histogram of the mean uptake in the segments of Bull's-eye image were compared before and after chemotherapy. The relationship of changes in these indices with the cumulative dose of doxorubicin, age and body mass index of the patients were also investigated.
Results: The mean percentage of uptake in the Bull's-eye segments was 69.60 before and 68.10 after chemotherapy (P>0.05). The standard deviation and 95% bandwidth of histogram of the mean segmental uptake before chemotherapy were 5.48 and 18.58, respectively, which increased to 5.56 and 19.52, respectively, after chemotherapy. This increase was mainly seen in patients who received a cumulative dose of more than 400 mg of doxorubicin. However, none of these changes were statistically significant (P>0.05). No significant association was observed between changes in left ventricular perfusion distribution and either age or body mass index.
Conclusion: Chemotherapy did not produce significant early changes in left ventricular myocardial perfusion. However, further studies with pixel-based myocardial perfusion imaging are recommended.
Keywords: Perfusion distribution, Cardiotoxicity, Chemotherapy, Myocardial perfusion scan, Breast cancer
Type of Study: Original |
Subject:
nuclear medicine
Received: 2026/04/12 | Accepted: 2026/06/10 | Published: 2026/07/8
Received: 2026/04/12 | Accepted: 2026/06/10 | Published: 2026/07/8
References
1. Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Front Public Health 2025; 13: 1622954. [DOI]
2. Alizadeh M, Ghojazadeh M, Piri R, et al. Age at Diagnosis of Breast Cancer in Iran: A Systematic Review and Meta-Analysis. Iran J Public Health 2021; 50(8): 1564-1576. [DOI]
3. Costa Viera R.A, Biller G, Uemura G, et al. Breast cancer screening in developing countries. Clinics 2017; 72(4): 244-253. [DOI]
4. Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985-2016. Breast 2017; 31: 46-50. [DOI]
5. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cariooncology prevention. J Natl Cancer Inst 2010; 102(1): 14-25. [DOI]
6. Thavendiranathan P, Poulin F, Lim KD, et all. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol 2014; 63(25 Pt A): 2751-2768. [DOI]
7. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97(11): 2869-2879. [DOI]
8. Soujeri B, Singh J, Chew S, et al. Surveillance and incidence of chemotherapy-induced cardiotoxicity in breast cancer: A long term observation study. Heart 2016; 102(6): A14-A15. [DOI]
9. Morelli MB, Bongiovanni C, Da Pra S, et al. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection. Front Cardiovasc Med 2022; 9: 847012. [DOI]
10. Armenian S.H, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J clin Oncol 2017; 35(8): 893-911. [DOI]
11. Abdel-Qadir H, Amir E, Thavandiranathan P. Prevention, detection and management of chemotherapy-related cardiac dysfunction. Can J Cardiol 2016; 32(7): 891-899. [DOI]
12. Tajiri K, Aonuma K, Sekine I. Cardio Oncology: a multidisciplinary approach for detection, prevention and management of cardiac dysfunction in cancer patients. Jap J Clin Oncol 2017; 47(8): 678-682. [DOI]
13. Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection and treatment. CA Cancer J Clin 2016; 66(4): 309-325. [DOI]
14. Schroder J, Prescott E. Doppler Echocardiography Assessment of Coronary Microvascular Function in Patients With Angina and No Obstructive Coronary Artery Disease. Front Cardiovasc Med 2021; 8: 723542. [DOI]
15. Russell R.R, Alexander J, Jain D, et al. The role and clinical effectiveness of multimodality imaging in the management of cardiac complications of can-cer and cancer therapy. J Nucl Cardiol 2016; 23(4): 856-884. [DOI]
16. Chen-Scarabelli C, McRee C, Leesar M.A, et.al. Comprehensive review on cardio-oncology: Role of multimodality imaging. J Nucl Cardiol 2017; 24(3): 906–935. [DOI]
17. Kirk JA, Kass DA. Electromechanical dyssynchrony and resynchronization of the failing heart. Crc Res 2013; 113(6): 765-776. [DOI]
18. Sharma RK, Volpe G, Rosen BD, et al. Prognostic implication of left ventricular dyssynchrony for major adverse cardiovascular events in asymptomatic women and men: The multi-Ethic study of Athero-sclerosis. J Am Heart Assoc 2014; 3(4): e000975. [DOI]
19. Hage FG, Aggarwal H, Patel K, et al. The relation-ship of left ventricular mechanical dyssynchrony and cardiac sympathetic denervation to potential sudden cardiac death events in systolic heart failure. J Nucl Cardiol 2014; 21(1): 78-85. [DOI]
20. Derakhshan S, Ghaderi B, Roshani D. Left ventricular mechanical dyssynchrony after chemotherapy in breast cancer patients with normal rest gated SPECT-MPI. Ann Nucl Med 2024; 38(4): 272-277. [DOI]
21. Paulus W J, Zile M R. From systemic inflammation to myocardial fibrosis: the heart failure with pre-served ejection fraction paradigm revisited. Circ Res 2021; 128(10): 1451-1467. [DOI]
22. Derakhshan S, Moassesghafari M, Rahmani Kh. Evaluation of heart rate and pulmonary uptake in dipyridamole myocardial perfusion imaging in patients with suspected coronary artery disease and their relationship with clinical risk factors. Iran South Med J 2025; 27(3): 205-214. [DOI]
23. Kuronuma K, Miller RJH, Van Kriekinge SD, et al. Incremental prognostic value of stress phase entropy over standard PET myocardial perfusion imaging variables. Eur J Nucl Med Mol imaging 2023; 50(12): 3619-3629. [DOI]
24. Contaldi C, Montesarchio V, Catapano D, et al. Multimodality Cardiovascular Imaging of Cardiotoxicity Due to Cancer Therapy. Life (Basel) 2023; 13(10): 2103. [DOI]
25. Galán-Arriola C, Vílchez-Tschischke JP, Lobo M, et al. Coronary microcirculation damage in anthracycline cardiotoxicity. Cardiovasc Res 2022; 118(2): 531-541. [DOI]
26. Cadour F, Thuny F, Sourdon J. New Insights in Early Detection of Anticancer Drug-Related Cardiotoxicity Using Perfusion and Metabolic Imaging. Front Car-diovasc Med 2022; 9: 813883. [DOI]
27. Kalábová H, Melichar B, Ungermann L, et al. Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy. Med Oncol 2011; 28(4): 1281-1287. [DOI]
28. Wenning C, Vrachimis A, Dell Aquila A, et al. Inhomogeneous myocardial stress perfusion in SPECT studies predicts future allograft dysfunction in heart transplant recipients. EJNMMI Res 2015; 5(1): 51. [DOI]
29. Jiang Z, Bu J, Zhao Z, et al. Texture Analysis of SPECT-MPI Provides Prognostic Value in Improving Cardiac Resynchronization Therapy Response. Pac-ing Clin Electrophysiol 2025; 48(6): 630-639. [DOI]
30. Ibrahim EH, Chaudhary L, Cheng YC, et al. Cardiac MRI for differentiating chemotherapy-induced cardiotoxicity in sarcoma and breast cancer. Radiol Oncol 2025; 59(1): 79-90. [DOI]
31. Li, H, Qin, X., Wang Y, et al. Cardiac magnetic resonance imaging for evaluating subclinical cardiotoxicity following chemotherapy in postoperative breast cancer patients. Thorac. Radiol 2026; 1(1): 100002. [DOI]
32. Safaei AM, Kamangar TM, Asadian S, et al. Detection of the Early Cardiotoxic Effects of Doxorubicin-Containing Chemotherapy Regimens in Patients with Breast Cancer through Novel Cardiac Magnet-ic Resonance Imaging: A Short-term Follow-up. J Clin Imaging Sci 2021; 11: 33. [DOI]
33. Henriksen PA. Anthracycline cardiotoxicity: an up-date on mechanisms, monitoring and prevention. Heart 2018; 104(12): 971-977. [DOI]
34. Folco G, Monti CB, Zanardo M, et al. MRI-derived extracellular volume as a biomarker of cancer therapy cardiotoxicity: systematic review and meta-analysis. Eur Radiol 2024; 34(4): 2699-2710. [DOI]
35. Valzania C, Paccagnella A, Spadotto A, et al. Early detection of cancer therapy cardiotoxicity by radio-nuclide angiography: An update. J Nucl Cardiol 2023; 30(5): 2104-2111. [DOI]
36. McGowan JV, Chung R, Maulik A, et al. Anthracy-cline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther 2017; 31(1): 63-75. [DOI]
37. Henry ML, Niu J, Zhang N, et al. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients. JACC Cardiovasc Imaging 2018; 11(8): 1084-1093. [DOI]
38. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43(41): 4229-4361. [DOI]
39. Kato Y, Chehab O, Ambale-Venkatesh B, et al. Quantitative myocardial perfusion imaging across PET, SPECT, CMR, and CT. Front Radiol 2026; 6: 1760241. [DOI]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
